Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Biology and Signal Transduction

Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression

Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-hua Liu, Er-bao Zhang, Kai-hua Lu and Yong-qian Shu
Feng-qi Nie
1Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Sun
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin-song Yang
3Department of Oncology, Nanjing First Hospital, Nanjing Medical University, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Xie
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong-peng Xu
1Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rui Xia
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan-wen Liu
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang-hua Liu
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Er-bao Zhang
2Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-hua Lu
1Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tgzy111@126.com yongqian_shu@163.com
Yong-qian Shu
1Department of Oncology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tgzy111@126.com yongqian_shu@163.com
DOI: 10.1158/1535-7163.MCT-14-0492 Published January 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Relative ANRIL expression in NSCLC tissues and its clinical significance. A, relative expression of ANRIL in NSCLC tissues (n = 68) compared with corresponding nontumor tissues (n = 68). ANRIL expression was examined by qPCR and normalized to GAPDH expression. Results are presented as the fold change in tumor tissues relative to normal tissues. B, ANRIL expression was classified into two groups. C and D, Kaplan–Meier DFS and OS curves according to ANRIL expression levels.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effects of knockdown of ANRIL on NSCLC cell viability in vitro. A, ANRIL expression levels of NSCLC cell lines (PC9, SPC-A1, NCI-H1975, H1299, and H358 and H520) compared with that in normal human bronchial epithelial cells (16HBE). B, SPC-A1, H1299, and PC9 cells were transfected with si-ANRIL. C, MTT assays were used to determine the cell viability for si-ANRIL–transfected SPC-A1, H1299, and PC9 cells. Values represent the mean ± SD from three independent experiments. D, colony-forming assays were conducted to determine the proliferation of si-ANRIL–transfected SPC-A1, H1299, and PC9 cells. Flow-cytometry assays were performed to analysis the cell-cycle progression and apoptosis when NSCLC cells transfected with si-ANRIL; *, P < 0.05 and **, P < 0.01.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effects of knockdown of ANRIL on NSCLC cell cycle and apoptosis in vitro. A, the bar chart represents the percentage of cells in G0–G1, S, or G2–M phase, as indicated. B, apoptosis was determined by flow cytometry; upper left, necrotic cells; upper right, terminal apoptotic cells; lower right, early apoptotic cells. C, apoptosis was determined by Tunel staining. All experiments were performed in biologic triplicates with three technical replicates; **, P < 0.01.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effects of downregulation of ANRIL on tumor growth in vivo. A, the tumor volume was calculated once every 3 days after injection of PC9 cells stably transfected with sh-ANRIL or empty vector. Points, mean (n = 7); bars, SD. B, tumor weights are represented as means of tumor weights ± SD. C, qPCR analysis of ANRIL expression in tumor tissues formed from PC9/sh-ANRIL, PC9/empty vector. D, tumors developed from sh-ANRIL–transfected PC9 cells showed lower Ki67 protein levels than tumors developed by control cells. Top, H&E staining; bottom, immunostaining; *, P < 0.05 and **, P < 0.01.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    ANRIL could silence KLF2 and P21 expression. A, the levels of p15INK4B and p16 mRNA were determined by qPCR in SPC-A1 and PC9 cells transfected with si-ANRIL and results are expressed relative to the corresponding values for control cells. B and C, the levels of p21 and KLF2 mRNA and protein levels were determined by qPCR and Western blot when PC9 cells were transfected with si-EZH2 or si-SUZ12. D, ANRIL expression levels in cell cytoplasm or nucleus of NSCLC cell lines SPC-A1, PC9, and H520 were detected by qPCR. *, P < 0.05 and **, P < 0.01; N.S., not significant.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    ANRIL could directly bind PRC2 and silence KLF2 and P21 transcription. A, RIP with rabbit monoclonal anti-EZH2, preimmune IgG, or 10% input from PC9 cell extracts. RNA levels in immunoprecipitates were determined by qPCR. Expression levels of ANRIL RNA are presented as fold enrichment in EZH2 relative to IgG immunoprecipitates; relative RNA levels of U1 snRNA in SNRNP70 relative to IgG immunoprecipitates were used as positive control. B and C, ChIP–qPCR of EZH2 occupancy and H3K27-3me binding in the KLF2 promoter in PC9 cells, and IgG as a negative control; ChIP–qPCR of EZH2 occupancy and H3K27-3me binding in the KLF2 promoter in PC9 cells treated with ANRIL siRNA (48 hours) or scrambled siRNA. D, analysis of the relationship between ANRIL expression and KLF2 mRNA level (ΔCt value) in 40 NSCLC tissues. The mean values and SDs were calculated from triplicates of a representative experiment.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Overexpression of KLF2 expression inhibits PC9 cells proliferation. PC9 cells were transfected with pCDNA–KLF2 or cotransfected with si-ANRIL and si-KLF2. A, the protein level of KLF2 in PC9 cells transfected with pCDNA–KLF2 was detected by Western blot analysis. B, MTT assays and colony-forming assays were used to determine the cell viability for pCDNA–KLF2-transfected PC9 cells. Values represent the mean ± SD from three independent experiments. C, apoptosis was determined by flow cytometry. Upper left, necrotic cells; upper right, terminal apoptotic cells; lower right, early apoptotic cells. D, the protein level of KLF2 in PC9 cells cotransfected with si-ANRIL and si-KLF2 was detected by Western blot analysis. E, MTT assays and colony-forming assays were used to determine the cell viability for si-ANRIL and si-KLF2 cotransfected PC9 cells. Values represent the mean ± SD from three independent experiments; *, P < 0.05 and **, P < 0.01.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Correlation between ANRIL expression and clinicopathologic characteristics of NSCLC patients

    ANRIL
    CharacteristicsHigh, number of cases (34)Low, number of cases (34)χ2 test (P value)
    Age, y0.627
     ≤651719
     >651715
    Gender0.625
     Male1820
     Female1614
    Histologic subtype0.324
     SCC2218
     Adenocarcinoma1216
    TNM stage0.007a
     Ia + Ib415
     IIa + IIb1412
     IIIa167
    Tumor size0.001a
     ≤5 cm1326
     >5 cm218
    Lymph node metastasis0.051
     Negative1119
     Positive2315
    Smoking history0.793
     Smokers2324
     Never smokers1110
    • ↵aOverall P < 0.05.

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Fig. S1 Legend - Supplementary Fig. S1 Legend
    • Supplementary figure 1 - Supplementary figure 1. The effect of ANRIL on cells proliferation and migration
    • Supplementary table 1 - Supplementary table 1. Univariate and multivariate analysis of progression-free survival in NSCLC patients (n=68)
    • Supplementary table 2 - Supplementary table 2. Univariate and multivariate analysis of overall survival in NSCLC patients (n=68)
    • Supplementary table 3 - Supplementary table 3. Sequence of primers and siRNA
    • Supplementary table 4 - Supplementary table 4. The raw data of ANRIL expression level in all patients
PreviousNext
Back to top
Molecular Cancer Therapeutics: 14 (1)
January 2015
Volume 14, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-hua Liu, Er-bao Zhang, Kai-hua Lu and Yong-qian Shu
Mol Cancer Ther January 1 2015 (14) (1) 268-277; DOI: 10.1158/1535-7163.MCT-14-0492

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-hua Liu, Er-bao Zhang, Kai-hua Lu and Yong-qian Shu
Mol Cancer Ther January 1 2015 (14) (1) 268-277; DOI: 10.1158/1535-7163.MCT-14-0492
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Ormeloxifene and Prostate Cancer
  • Proinflammatory Cytokines and Drug Resistance
  • ABCB1 Confers Cross-Resistance to Cabazitaxel and Docetaxel
Show more Cancer Biology and Signal Transduction
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement